Skip to main content
. 2022 Feb 9;12:2208. doi: 10.1038/s41598-022-05688-9

Table 3.

Risk of secondary endpoints according to atrial fibrillation type.

Outcome No. of events Incidence, per 100py Hazard ratio (95% CI)
Age and sex adjusted p value Multivariable adjusted p value
Congestive heart failure hospitalization
Paroxysmal 133 2.1 Ref Ref
Persistent 86 3.1 1.47 (1.12; 1.93) 0.006 1.34 (1.00; 1.80) 0.05
Permanent 144 5.5 1.78 (1.39; 2.26) < 0.001 1.30 (1.01; 1.67) 0.04
Myocardial infarction
Paroxysmal 41 0.6 Ref Ref
Persistent 15 0.5 0.81 (0.45; 1.47) 0.49 0.91 (0.48; 1.72) 0.77
Permanent 28 1.0 1.10 (0.67; 1.80) 0.71 0.95 (0.56; 1.59) 0.84
MACE
Paroxysmal 134 2.1 Ref Ref
Persistent 73 2.6 1.23 (0.92; 1.64) 0.15 1.15 (0.85; 1.57) 0.37
Permanent 145 5.3 1.75 (1.37; 2.23) < 0.001 1.41 (1.10; 1.82) 0.008
All-cause mortality
Paroxysmal 122 1.9 Ref Ref
Persistent 68 2.4 1.28 (0.95; 1.72) 0.11 1.23 (0.89; 1.69) 0.21
Permanent 147 5.2 1.80 (1.40; 2.30) < 0.001 1.45 (1.12; 1.87) 0.005
Major bleeding
Paroxysmal 99 1.6 Ref Ref
Persistent 51 1.8 1.19 (0.85; 1.68) 0.31 1.11 (0.76; 1.61) 0.59
Permanent 71 2.6 1.17 (0.86; 1.61) 0.32 0.98 (0.71; 1.36) 0.90
Non-major bleeding
Paroxysmal 150 2.4 Ref Ref
Persistent 69 2.5 1.03 (0.77; 1.37) 0.86 0.82 (0.60; 1.12) 0.21
Permanent 117 4.5 1.38 (1.07; 1.77) 0.01 1.02 (0.79; 1.33) 0.86
Any bleeding
Paroxysmal 237 3.9 Ref Ref
Persistent 112 4.1 1.06 (0.85; 1.33) 0.61 0.89 (0.70; 1.14) 0.37
Permanent 174 6.9 1.28 (1.05; 1.57) 0.02 1.00 (0.81; 1.24) 1.00

Data are hazard ratios (HR) (95% confidence intervals [CI]). p-values were based on Cox regression models.

No. number, Ref. reference, py patient years, MACE major adverse cardiovascular event (Ischaemic stroke/myocardial infarction/cardiovascular death). P-values are based on Cox regression models. Multivariable models were adjusted for age, sex, heart rate and time-updated: smoking status (current vs. history/never smoker), BMI, history of diabetes, history of coronary artery disease, history of hypertension, history of heart failure, history of stroke and/or transient ischemic attack, history of renal failure, oral anticoagulation, antiplatelet therapy, history of pulmonary vein isolation and history of electrical cardioversion.